
    
      The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
      repeat ascending doses of GSK2018682. The study will also provide further evidence of the
      potential therapeutic dose-range by measuring the inhibitory effect of GSK2018682 on Absolute
      Lymphocyte Counts (ALC).
    
  